Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VCNX

Vaccinex Inc

Dec 12 • 12:31PM ET

4.10

Dollar change +0.05
Percentage change 1.23	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA JNJ AZN BNTX GSK SNY NVAX ALT VXRT

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.58	Insider Own	49.16%	Shs Outstand	2.60M	Perf Week	17.82%
Market Cap	10.66M	Forward P/E	-	EPS next Y	-	Insider Trans	20.60%	Shs Float	1.32M	Perf Month	23.12%
Income	-18.58M	PEG	-	EPS next Q	-	Inst Own	12.91%	Short Float	4.71%	Perf Quarter	-26.93%
Sales	0.39M	P/S	27.33	EPS this Y	-	Inst Trans	63.34%	Short Ratio	0.57	Perf Half Y	-43.06%
Book/sh	-1.09	P/B	-	EPS next Y	-	ROA	-501.27%	Short Interest	0.06M	Perf Year	-47.70%
Cash/sh	1.12	P/C	3.66	EPS next 5Y	-	ROE	-759.09%	52W Range	1.39 - 13.02	Perf YTD	-55.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.34%	ROI	-	52W High	-68.51%	Beta	1.09
Dividend TTM	-	Quick Ratio	0.77	Sales past 5Y	14.71%	Gross Margin	73.58%	52W Low	194.96%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	0.77	EPS Y/Y TTM	85.01%	Oper. Margin	-5241.24%	RSI (14)	56.72	Volatility	13.01% 13.38%
Employees	40	Debt/Eq	-	Sales Y/Y TTM	-51.19%	Profit Margin	-4787.89%	Recom	1.00	Target Price	21.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	81.47%	Payout	-	Rel Volume	0.26	Prev Close	4.05
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	160.00%	Earnings	-	Avg Volume	108.04K	Price	4.10
SMA20	9.28%	SMA50	27.27%	SMA200	-23.99%	Trades		Volume	13,739	Change	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-20	Downgrade	BTIG Research	Buy → Neutral
Sep-04-18	Initiated	Ladenburg Thalmann	Buy	$22

Nov-18-24 08:30AM	Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 08:30AM	Vaccinex Provides Update on ActivMAb Platform: Multiple Project Deals and Presentation at SITC (GlobeNewswire)
Nov-05-24 08:30AM	Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting (GlobeNewswire)
Oct-31-24 10:00AM	Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain (GlobeNewswire) -30.77%
Oct-24-24 08:30AM	Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024 (GlobeNewswire) +24.18%
08:30AM	Loading…
Sep-18-24 08:30AM	Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds (GlobeNewswire) -14.00%
Aug-14-24 08:30AM	Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership (GlobeNewswire) +9.94%
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +7.61%
Jul-31-24 12:53PM	Vaccinexs Phase Ib/II trial for Alzheimers treatment hits primary endpoint (Clinical Trials Arena) -36.72%
09:00AM	Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease (GlobeNewswire)
Jul-17-24 08:00AM	Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024 (GlobeNewswire) +12.50%
Jun-06-24 08:30AM	Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease (GlobeNewswire) +7.64%
May-16-24 06:52AM	VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024 (InvestorPlace)
May-15-24 06:00PM	Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-02-24 01:52PM	VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023 (InvestorPlace)
08:30AM	Loading…
08:30AM	Vaccinex Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-24 08:30AM	Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Feb-21-24 08:00AM	Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology (GlobeNewswire) +5.48%
Feb-15-24 08:00AM	Vaccinex, Inc. Announces Reverse Stock Split (GlobeNewswire)
Feb-12-24 11:03AM	Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc (GuruFocus.com) +9.00%
Feb-07-24 08:00AM	Vaccinex Announces Pricing of $3.7 Million PIPE Financing (GlobeNewswire)
Dec-04-23 08:00AM	Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule (GlobeNewswire) +17.58%
Nov-13-23 08:00AM	Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 09:00AM	Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting (GlobeNewswire)
Oct-26-23 09:30AM	Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases (GlobeNewswire)
Oct-06-23 08:08AM	Why Is Vaccinex (VCNX) Stock Up 26% Today? (InvestorPlace) +34.11%
Sep-28-23 09:00PM	Vaccinex Announces Pricing of $9.6 Million Public Offering (GlobeNewswire) +34.82% -25.17%
08:00AM	Vaccinex s Next Generation ActivMAb Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration (GlobeNewswire)
Sep-27-23 08:00AM	Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb Application (GlobeNewswire) -11.11%
Sep-26-23 08:00AM	Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer (GlobeNewswire) -26.64%
04:30PM	Loading…
Sep-22-23 04:30PM	Vaccinex, Inc. Announces Reverse Stock Split (GlobeNewswire) -26.03%
Aug-14-23 08:10AM	Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.53%
Jun-01-23 08:00AM	Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET (GlobeNewswire)
May-15-23 04:45PM	Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.50%
Apr-25-23 08:00AM	Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimers Disease) Study of Pepinemab (GlobeNewswire)
Apr-12-23 08:00AM	Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells (GlobeNewswire)
Apr-03-23 08:30AM	Vaccinex Announces Private Placement with Commitments of $5.0 Million (GlobeNewswire) +5.63%
08:00AM	Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs (GlobeNewswire)
Mar-23-23 08:00AM	Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference (GlobeNewswire)
Mar-21-23 08:30AM	Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (GlobeNewswire)
Mar-09-23 08:00AM	Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis (GlobeNewswire) -6.88%
Jan-26-23 06:06PM	The 3 Best Biotech Stocks Under $1 to Buy for January (InvestorPlace)
Jan-09-23 08:00AM	Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology (GlobeNewswire)
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey) -6.74% +9.93%
Nov-28-22 08:00AM	Vaccinex Announces $3.8 Million Private Placement (GlobeNewswire) +9.79%
Nov-16-22 05:38AM	Vaccinex Third Quarter 2022 Earnings: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021) (Simply Wall St.) -11.37%
Nov-14-22 08:30AM	Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
Nov-10-22 09:00AM	Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-03-22 06:16AM	Companies Like Vaccinex (NASDAQ:VCNX) Could Be Quite Risky (Simply Wall St.)
Aug-15-22 08:10AM	Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs (GlobeNewswire)
Aug-08-22 11:00AM	Vaccinex, Inc.s Phase 2 SIGNAL Study to Evaluate Pepinemab Antibody in Huntingtons Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation (GlobeNewswire) +5.83%
Jul-29-22 07:00AM	Vaccinex, Inc. Announces Presentation at the 2022 Alzheimers Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimers Disease (GlobeNewswire)
Jul-21-22 08:21AM	Multiple insiders bought Vaccinex, Inc. (NASDAQ:VCNX) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-25-22 08:00AM	Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET (GlobeNewswire)
May-16-22 08:15AM	Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
Apr-25-22 08:00AM	Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery (GlobeNewswire)
Mar-31-22 09:15AM	Vaccinex Reports 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-22 09:00AM	Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) +19.27%
Feb-24-22 08:00AM	Vaccinex, Inc. to Present at CHDIs 17th Annual HD Therapeutics Conference Meeting (GlobeNewswire)
Feb-11-22 11:24AM	With stock up 25%, Insiders of Vaccinex, Inc. (NASDAQ:VCNX) must be wishing they had bought more last year (Simply Wall St.) -8.76%
Jan-28-22 07:57AM	Vaccinex's CEO, Chairman To Inject $4M To Fund The Lead Program (Benzinga) +23.50%
Jan-27-22 04:15PM	Vaccinex Announces $6.6 Million Private Placement (GlobeNewswire) -17.57%
Jan-26-22 11:18AM	Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer (Benzinga) +8.82%
08:00AM	Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire)
Jan-04-22 08:00AM	Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis (GlobeNewswire)
Nov-10-21 08:00AM	Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting (GlobeNewswire)
Nov-09-21 08:00AM	Vaccinex, Inc. to Present at the Clinical Trials on Alzheimers Disease (CTAD) Meeting (GlobeNewswire)
Nov-08-21 08:15AM	Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:00AM	Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-21 08:00AM	Vaccinex to Present at the Virtual Huntingtons Study Group Meeting on November 4-6, 2021 (GlobeNewswire)
Sep-17-21 08:00AM	Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Sep-15-21 08:00AM	Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntingtons Disease Network Meeting (GlobeNewswire)
Aug-16-21 08:15AM	Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-21-21 07:45AM	A Look At Vaccinex's (NASDAQ:VCNX) Share Price Returns (Simply Wall St.)
Jun-30-21 08:00AM	Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease (GlobeNewswire)
Jun-08-21 07:57AM	Vaccinex Initiates Pepinemab Trials for Alzheimer's, Head & Neck Cancer (Benzinga)
07:00AM	Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimers Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire)
May-19-21 08:00AM	Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference (GlobeNewswire)
May-17-21 08:15AM	Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-21-21 08:00AM	Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research (GlobeNewswire) +7.33%
Mar-16-21 08:05AM	Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-21 08:00AM	Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire) +7.47%
Feb-23-21 07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts (Benzinga) -21.92%
Feb-22-21 08:30AM	Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology (GlobeNewswire)
Feb-19-21 12:20PM	Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers (MarketWatch) +70.03%
10:36AM	VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring (InvestorPlace)
07:30AM	Vaccinex Spikes on Deals with Two Pharma Companies (TheStreet.com)
Jan-07-21 08:19AM	Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech (Zacks) +6.19%
Jan-06-21 08:43AM	Bet on Rising P/E With These 5 Top-Ranked Stocks (Zacks)
Jan-05-21 08:00AM	Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event (GlobeNewswire)
Nov-13-20 08:05AM	Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-20 11:15AM	CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference (GlobeNewswire)
Oct-26-20 07:55AM	Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable (GlobeNewswire) +6.38%
Oct-12-20 08:53AM	Implied Volatility Surging for Vaccinex (VCNX) Stock Options (Zacks) -5.86%
Sep-23-20 10:34AM	Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More (Zacks) -19.83%
Sep-22-20 08:40AM	Vaccinex's stock falls after investigational drug fails Huntington's disease study (MarketWatch) -57.59%
07:30AM	Top-Line Results of Phase 2 SIGNAL Study in Huntingtons Disease Support Potential for Cognitive Benefit of Pepinemab (GlobeNewswire)
Sep-17-20 08:00AM	Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +12.10%
Aug-27-20 08:00AM	Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer (GlobeNewswire)
Aug-14-20 09:45AM	Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.84%

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington's disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zauderer Maurice	President and CEO	Sep 18 '24	Option Exercise	5.64	113,650	640,531	251,788	Sep 20 04:14 PM
FRIEDBERG ALBERT	Director	Sep 18 '24	Option Exercise	5.64	240,009	1,352,691	1,020,633	Sep 20 04:11 PM
FRIEDBERG ALBERT	Director	Aug 09 '24	Buy	4.51	100	451	780,624	Aug 13 04:30 PM
FRIEDBERG ALBERT	Director	Aug 05 '24	Buy	4.60	3,653	16,804	777,771	Aug 07 04:04 PM
FRIEDBERG ALBERT	Director	Aug 06 '24	Buy	4.92	2,753	13,545	780,524	Aug 07 04:04 PM
FRIEDBERG ALBERT	Director	Aug 01 '24	Buy	4.72	11,703	55,238	774,118	Aug 02 04:05 PM
FRIEDBERG ALBERT	Director	Jul 31 '24	Buy	6.15	200,000	1,230,280	762,415	Aug 01 04:05 PM
FRIEDBERG ALBERT	Director	May 29 '24	Buy	4.95	957	4,737	561,554	May 31 04:31 PM
FRIEDBERG ALBERT	Director	May 30 '24	Buy	5.20	861	4,473	562,415	May 31 04:31 PM
FRIEDBERG ALBERT	Director	Apr 19 '24	Buy	4.73	282	1,334	560,597	Apr 22 04:33 PM
Van Strydonck, Gerald E.	Director	Dec 26 '23	Sale	0.72	3,149	2,267	0	Dec 28 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCNX

Vaccinex Inc

Upgrade your FINVIZ experience